Enrique Seda
Research Subjects
Enrique Seda has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Felipe Javier Chaves
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain
3 shared publications - Sebastian Blesa
Genomics and Genetic Diagnosis Unit, Research Foundation, Hospital Clínico Universitario de Valencia-INCLIVA, Valencia, Spain
3 shared publications - Esteban J. Morcillo
CIBERES, Health Institute Carlos III, Valencia, Spain
2 shared publications - Manuel Mata
Department of Pathology, Faculty of Medicine and Dentistry, Universitat de València, 46010 Valencia, Spain
2 shared publications Alicia Serrano
Hematology Department, Hospital Clínico Universitario Valencia, INCLIVA Research Institute, University of Valencia, Avenida Blasco Ibáñez, 17, 46010, Valencia, Spain
1 shared publication- Alicia Serrano Alcalá
Hematology Department Hospital Clínico Universitario de Valencia Valencia Spain
1 shared publication
Latest Publications
- Open Access
- 1 April 2025
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 23 (2)
Characterization of Chronic Lymphocytic Leukemia Immunoglobulin Rearrangements from Partial Read Sequencing
The determination of the mutational status in the immunoglobulin variable region is an established prognostic biomarker for chronic lymphocytic leukemia (CLL). The length and inner variability of the variable, diversity, and joining (VDJ) rearranged sequences compromise B-cell clone characterization using next-generation sequencing (NGS), and a standardization is needed to adapt the procedure to the current clinical guidelines. Here, we develop a complete strategy for sequencing the variable domain of the immunoglobulin heavy chain (IGH) locus with a simple, low-cost, and efficient method that enables sequencing using shorter reads (MiSeq 150 × 2), allowing for faster results. Clonality and mutational status determination are performed within the same analysis pipeline. We tested and validated the method using 319 CLL patients previously diagnosed with IGH locus characterized using Sanger sequencing, along with 47 healthy donor samples. The analysis method follows a clone-centered consensus sequence strategy to identify B-cell clones and establish a clonal threshold specific for each patient’s clonality profile, thereby overcoming the limitations of Sanger sequencing which is the gold standard used for determining immunoglobulin heavy variable (IGHV) mutational status.
- 1 April 2025
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 23 (2)
Open AccessCharacterization of Chronic Lymphocytic Leukemia Immunoglobulin Rearrangements from Partial Read Sequencing
The determination of the mutational status in the immunoglobulin variable region is an established prognostic biomarker for chronic lymphocytic leukemia (CLL). The length and inner variability of the variable, diversity, and joining (VDJ) rearranged sequences compromise B-cell clone characterization using next-generation sequencing (NGS), and a standardization is needed to adapt the procedure to the current clinical guidelines. Here, we develop a complete strategy for sequencing the variable domain of the immunoglobulin heavy chain (IGH) locus with a simple, low-cost, and efficient method that enables sequencing using shorter reads (MiSeq 150 × 2), allowing for faster results. Clonality and mutational status determination are performed within the same analysis pipeline. We tested and validated the method using 319 CLL patients previously diagnosed with IGH locus characterized using Sanger sequencing, along with 47 healthy donor samples. The analysis method follows a clone-centered consensus sequence strategy to identify B-cell clones and establish a clonal threshold specific for each patient’s clonality profile, thereby overcoming the limitations of Sanger sequencing which is the gold standard used for determining immunoglobulin heavy variable (IGHV) mutational status.
- 28 January 2020
- Published by Springer Nature in Annals of Hematology
- Vol. 99 (3) , 527-537
Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine
Azacitidine (AZA) is a DNA hypomethylation agent administered in myeloid neoplasms; however, there is still a lack of established predictors of response. We studied 113 patients with myelodysplastic syndromes (n = 85) or acute myeloid leukemia (n = 28) who received AZA to assess the predictive value on response of clinical features, cytogenetics, and molecular markers. Overall, 46 patients (41%) responded to AZA. Platelet doubling after the first AZA cycle was associated with a better response (68% vs. 32% responders, P = 0.041). Co-occurrence of chromosome 7 abnormalities and 17p deletion was associated with a worse response (P = 0.039). Pre-treatment genetic mutations were detected in 98 patients (87%) and methylation of CDKN2B and DLC-1 promoters were detected in 50 (44%) and 37 patients (33%), respectively. Patients with SF3B1 mutations showed a better response to AZA (68% vs. 35% responders, P = 0.008). In contrast, subjects with mutations in transcription factors (RUNX1, SETBP1, NPM1) showed a worse response (20% vs. 47% responders, P = 0.014). DLC-1 methylation pre-treatment was associated with poor clinical features and its reduction post-treatment resulted in a better response to AZA in MDS patients (P = 0.037). In conclusion, we have identified several predictors of response to AZA that could help select the best candidates for this treatment.
- 28 January 2020
- Published by Springer Nature in Annals of Hematology
- Vol. 99 (3) , 527-537
Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine
Azacitidine (AZA) is a DNA hypomethylation agent administered in myeloid neoplasms; however, there is still a lack of established predictors of response. We studied 113 patients with myelodysplastic syndromes (n = 85) or acute myeloid leukemia (n = 28) who received AZA to assess the predictive value on response of clinical features, cytogenetics, and molecular markers. Overall, 46 patients (41%) responded to AZA. Platelet doubling after the first AZA cycle was associated with a better response (68% vs. 32% responders, P = 0.041). Co-occurrence of chromosome 7 abnormalities and 17p deletion was associated with a worse response (P = 0.039). Pre-treatment genetic mutations were detected in 98 patients (87%) and methylation of CDKN2B and DLC-1 promoters were detected in 50 (44%) and 37 patients (33%), respectively. Patients with SF3B1 mutations showed a better response to AZA (68% vs. 35% responders, P = 0.008). In contrast, subjects with mutations in transcription factors (RUNX1, SETBP1, NPM1) showed a worse response (20% vs. 47% responders, P = 0.014). DLC-1 methylation pre-treatment was associated with poor clinical features and its reduction post-treatment resulted in a better response to AZA in MDS patients (P = 0.037). In conclusion, we have identified several predictors of response to AZA that could help select the best candidates for this treatment.
- 1 November 2017
- Published by Elsevier in Clinical Lung Cancer
- Vol. 18 (6) , e395-e402
Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients
- 1 November 2017
- Published by Elsevier in Clinical Lung Cancer
- Vol. 18 (6) , e395-e402
Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients
- 1 February 2002
- Published by Elsevier in Pharmacological Research
- Vol. 45 (2) , 135-140
Effectiveness of oral N -acetylcysteine in a rat experimental model of asthma
- 1 February 2002
- Published by Elsevier in Pharmacological Research
- Vol. 45 (2) , 135-140
Effectiveness of oral N -acetylcysteine in a rat experimental model of asthma
- 1 November 2001
- Published by Elsevier in European Journal of Pharmacology
- Vol. 431 (1) , 111-117
Effects of taurine on pulmonary responses to antigen in sensitized Brown–Norway rats
- 1 November 2001
- Published by Elsevier in European Journal of Pharmacology
- Vol. 431 (1) , 111-117
Effects of taurine on pulmonary responses to antigen in sensitized Brown–Norway rats